[Innovative treatment in oncology].
The improved knowledge of the key molecular mechanisms involved in cell transformation and tumor progression allows to the identification of new therapeutic targets for anticancer therapy. Several molecular-targeting compounds have been developed, capable to selectively interfire with tumorangiogenesis, receptors with tyrosin-chinase activity, specific tumor growth factors. A rationale selection of the patients as well as an appropriate monitoring of pharmacodynamics effects of molecular-targeting compounds need of the availability of surrogate markers, assessable in tumor tissue of circulating blood.
Capaccetti
Barbara
B
Unità Operativa di Oncologia Medica, Azienda Complesso Ospedaliero di Rilevanza Nazionale San Filippo Neri, Roma.
Bonginelli
Paola
P
Sarmiento
Roberta
R
Fanelli
Massimo
M
Longo
Raffaele
R
Gattuso
Domenico
D
Gasparini
Giampietro
G
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D015363:Quinolones / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D015363:Quinolones; D011505:Protein-Tyrosine Kinases; C402769:tipifarnib